Gelesis Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 07:00 am EDT
Share
Gelesis Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 8.97 million compared to USD 2.18 million a year ago. Net loss was USD 12.51 million compared to USD 24.74 million a year ago. Basic loss per share from continuing operations was USD 0.17 compared to USD 19.18 a year ago.
For the six months, revenue was USD 16.49 million compared to USD 5.28 million a year ago. Net loss was USD 18.22 million compared to USD 43.33 million a year ago. Basic loss per share from continuing operations was USD 0.83 compared to USD 28.54 a year ago.
Gelesis Holdings, Inc. is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of Functional Constipation (FC).
GELESIS HOLDINGS, INC. 
